# Novartis clinical trials: 714 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 714 trials with Novartis as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Novartis: 714 rows for $35.70, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/novartis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 714
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 714, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 26, 2024 | NCT06705504 | A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib | Novartis | Observational | Completed | Hormone Receptor Positive HER-2 Negative Breast Cancer | 435 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06705504) |
| November 4, 2024 | NCT06671314 | Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction | Novartis | Observational | Completed | Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction | 42,494 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06671314) |
| October 29, 2024 | NCT06662825 | Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers | Novartis | Observational | Completed | Sickle Cell Disease | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06662825) |
| October 29, 2024 | NCT06662812 | Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry | Novartis | Observational | Completed | Sickle Cell Disease | 1,665 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06662812) |
| October 16, 2024 | NCT06644638 | Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis | Novartis | Observational | Completed | Multiple Sclerosis | 3,632 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06644638) |
| October 9, 2024 | NCT06632730 | Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain | Novartis | Observational | Completed | Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06632730) |
| September 19, 2024 | NCT06600009 | Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database | Novartis | Observational | Completed | Psoriatic Arthritis | 534 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06600009) |
| September 19, 2024 | NCT06595069 | A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients | Novartis | Observational | Completed | Hypercholesterolemia | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06595069) |
| September 19, 2024 | NCT06588387 | A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis | Novartis | Observational | Completed | Secondary Progressive Multiple Sclerosis | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06588387) |
| August 16, 2024 | NCT06557291 | Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma | Novartis | Observational | Completed | BRAF V600 Mutated-Stage III/IV Melanoma | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06557291) |
| July 29, 2024 | NCT06526000 | Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies | Novartis | Observational | Completed | Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary... | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06526000) |
| July 23, 2024 | NCT06516029 | Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib | Novartis | Observational | Completed | Chronic Myeloid Leukemia, Chronic Phase | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06516029) |
| July 18, 2024 | NCT06507852 | A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With... | Novartis | Observational | Completed | Atherosclerotic Cardiovascular Disease, Hypercholesterolemia | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06507852) |
| June 18, 2024 | NCT06463626 | Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study | Novartis | Observational | Completed | Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06463626) |
| June 14, 2024 | NCT06459232 | Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies | Novartis | Observational | Completed | Multiple Sclerosis | 143 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06459232) |
| May 2, 2024 | NCT06395909 | A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis | Novartis | Observational | Completed | Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary... | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06395909) |
| April 17, 2024 | NCT06369428 | Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients | Novartis | Observational | Completed | Metastatic Melanoma | 1,795 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06369428) |
| April 28, 2015 | NCT02427750 | A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to... | Novartis | Phase 2 | Completed | Human Influenza | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02427750) |
| March 9, 2015 | NCT02382913 | Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113\_01 Extension 1) | Novartis | Phase 1 | Completed | Pertussis | 315 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02382913) |
| March 5, 2015 | NCT02379637 | Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough | Novartis | Phase 2 | Completed | Common Cold Associated With Cough | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02379637) |
| December 2, 2014 | NCT02305446 | Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ. | Novartis | Phase 3 | Completed | Meningitis, Meningococcal, Serogroup B | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02305446) |
| November 14, 2014 | NCT02290821 | Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries | Novartis | Phase 3 | Completed | Acute Blunt Soft Tissue Injuries/Contusions | 215 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02290821) |
| October 22, 2014 | NCT02271854 | A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing... | Novartis | Phase 3 | Completed | Muscle Soreness | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02271854) |
| September 10, 2014 | NCT02235740 | A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With... | Novartis | Phase 1 | Terminated | Cancer | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02235740) |
| June 27, 2014 | NCT02177032 | Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects... | Novartis | Phase 3 | Completed | Rabies Infection | 885 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02177032) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 68 |
| Phase 1/2 | 20 |
| Phase 2 | 104 |
| Phase 2/3 | 10 |
| Phase 3 | 297 |
| Phase 4 | 181 |
| Not applicable | 5 |
| Observational | 29 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 672 |
| Terminated | 30 |
| Withdrawn | 10 |
| Approved for marketing | 1 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypertension | 143 |
| Diabetes Mellitus, Type 2 | 47 |
| Pulmonary Disease, Chronic Obstructive | 28 |
| Influenza, Human | 24 |
| Asthma | 23 |
| Diabetes Mellitus | 15 |
| Alzheimer Disease | 15 |
| Dermatitis, Atopic | 14 |
| Osteoarthritis | 14 |
| Multiple Sclerosis | 12 |
| Essential Hypertension | 12 |
| Osteoporosis | 11 |
| Breast Neoplasms | 10 |
| Parkinson Disease | 10 |
| Metabolic Syndrome | 10 |
| Macular Degeneration | 9 |
| Pain | 8 |
| Dyspepsia | 7 |
| Constipation | 7 |
| Hepatitis B, Chronic | 7 |
| Choroidal Neovascularization | 7 |
| Urinary Bladder, Overactive | 7 |
| Dyslipidemias | 7 |
| Dementia | 7 |
| Arthritis, Rheumatoid | 7 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Endodontics practices in the United States](https://specstream.ai/data/businesses/endodontics-practices/united-states)
- [Social security law firms in the United States](https://specstream.ai/data/businesses/social-security-law-firms/united-states)
- [Equipment rental companies in the United States](https://specstream.ai/data/businesses/equipment-rental-companies/united-states)
- [Specialty schools in the United States](https://specstream.ai/data/businesses/specialty-schools/united-states)
- [Eye care clinics in the United States](https://specstream.ai/data/businesses/eye-care-clinics/united-states)
- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
